IL151496A0 - Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same - Google Patents

Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Info

Publication number
IL151496A0
IL151496A0 IL15149600A IL15149600A IL151496A0 IL 151496 A0 IL151496 A0 IL 151496A0 IL 15149600 A IL15149600 A IL 15149600A IL 15149600 A IL15149600 A IL 15149600A IL 151496 A0 IL151496 A0 IL 151496A0
Authority
IL
Israel
Prior art keywords
clarithromycin
processes
pharmaceutical composition
same
free
Prior art date
Application number
IL15149600A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL151496A0 publication Critical patent/IL151496A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15149600A 2000-02-29 2000-12-15 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same IL151496A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18588800P 2000-02-29 2000-02-29
US18912000P 2000-03-14 2000-03-14
US21323900P 2000-06-22 2000-06-22
PCT/US2000/033843 WO2001064224A1 (en) 2000-02-29 2000-12-15 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
IL151496A0 true IL151496A0 (en) 2003-04-10

Family

ID=27392028

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15149600A IL151496A0 (en) 2000-02-29 2000-12-15 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Country Status (15)

Country Link
US (3) US6617436B2 (sk)
EP (1) EP1313486A1 (sk)
JP (1) JP2004509062A (sk)
KR (1) KR20030047873A (sk)
AU (2) AU2578701A (sk)
CA (1) CA2401571A1 (sk)
CZ (1) CZ20023167A3 (sk)
HR (1) HRP20020709A2 (sk)
HU (1) HUP0302466A2 (sk)
IL (1) IL151496A0 (sk)
IS (1) IS6531A (sk)
PL (1) PL366021A1 (sk)
SK (1) SK13722002A3 (sk)
WO (1) WO2001064224A1 (sk)
YU (1) YU64202A (sk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DK1267840T3 (da) * 2000-03-28 2009-09-07 Sandoz Ag Granulerede partikler med maskeret smag
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
CN102417532A (zh) * 2011-12-20 2012-04-18 浙江国邦药业有限公司 一种泰利霉素关键中间体5-德胺糖基-6-o-甲基红霉素的合成方法
CN102718821B (zh) * 2012-06-27 2014-12-03 浙江国邦药业有限公司 一种克拉霉素合成过程中甲基化反应以及甲基化试剂的回收套用方法
CN103880901A (zh) * 2012-12-23 2014-06-25 菏泽市方明制药有限公司 一种克拉霉素中间甲化物的制备方法
CN106905204B (zh) * 2017-02-24 2018-07-20 杭州新桂实业有限公司 一种克拉霉素合成过程中甲基化反应溶剂的回收套用方法
CN108117573A (zh) * 2017-12-26 2018-06-05 宁夏启元药业有限公司 4"-o-（三甲基硅）红霉素a 9-o-（1-乙氧基-1-甲基乙基）肟的合成方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669236A (en) * 1900-02-16 1901-03-05 Frank M Garland Automatic machine-gun.
US3922379A (en) * 1973-12-17 1975-11-25 Abbott Lab Microencapsulation process
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
EP0056195B1 (en) * 1980-12-25 1986-06-18 Fujitsu Limited Nonvolatile semiconductor memory device
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
ATE66143T1 (de) * 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
TW276996B (sk) * 1992-04-24 1996-06-01 Astra Ab
WO1993024109A1 (en) * 1992-06-04 1993-12-09 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
US5837829A (en) * 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DE29724846U1 (de) 1996-07-29 2004-12-16 Abbott Laboratories, Abbott Park Herstellung von kristalliner Form II von Clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
DE19950781A1 (de) * 1999-10-21 2001-04-26 Knoll Ag Mehrteiliges Etikett für Durchdrückpackungen, seine Herstellung und Verwendung
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
PL356645A1 (en) 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU771825B2 (en) * 2000-03-15 2004-04-01 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
IN192748B (sk) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
ES2195727B1 (es) * 2001-07-05 2005-03-01 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
EP1492507A2 (en) * 2002-04-03 2005-01-05 Ranbaxy Laboratories, Ltd. Clarithromycin formulations having improved bioavailability
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics

Also Published As

Publication number Publication date
US7101858B2 (en) 2006-09-05
CA2401571A1 (en) 2001-09-07
AU2001225787B2 (en) 2005-12-08
JP2004509062A (ja) 2004-03-25
AU2578701A (en) 2001-09-12
HRP20020709A2 (en) 2004-12-31
KR20030047873A (ko) 2003-06-18
CZ20023167A3 (cs) 2003-10-15
AU2001225787C1 (en) 2006-09-21
EP1313486A1 (en) 2003-05-28
PL366021A1 (en) 2005-01-24
US20060205683A1 (en) 2006-09-14
US6617436B2 (en) 2003-09-09
WO2001064224A1 (en) 2001-09-07
IS6531A (is) 2002-08-28
YU64202A (sh) 2005-03-15
US20030216556A1 (en) 2003-11-20
HUP0302466A2 (hu) 2003-11-28
SK13722002A3 (sk) 2003-08-05
US20010037015A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2578701A (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
HK1045650A1 (en) Pharmaceutical composition.
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
MXPA03002070A (es) Proceso de anticoncepcion y forma de administracion para el mismo.
IL152448A0 (en) 3-nitrogen-6, 7-dioxygen steroid derivatives and pharmaceutical compositions containing the same
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
HK1047584A1 (en) Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process.
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
AU7773001A (en) Acylacetonitriles, process for preparation thereof and miticides containing the same
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
MXPA03000574A (es) Vidrios ceramizados, proceso para su preparacion y uso.
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
ZA200000857B (en) Pharmaceutical composition.
ZA200300743B (en) DDS compound and process for the preparation thereof.
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
HUP0200928A3 (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
IL154986A0 (en) Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
IL156861A0 (en) Pyrrole derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.
HRP20020047B1 (en) sTREPTOGRAMIN DERIVATIVES, PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME
AU2001260083A1 (en) New pharmaceutical composition and the process for its preparation
HK1052709A1 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof pluraflavin.